Cochrane

Get involved in the #WorldEBHCDay campaign as we lead up to 20 October! Create your own World EBHC Day social media tiles using the social media toolkit and messaging, available to download in various languages. Don’t forget to include hashtag #WorldEBHCDay and tag @WorldEBHCDay! Download the social media toolkit at https://lnkd.in/dER5iZDA and translated messaging in different languages at: https://lnkd.in/g-frpmyQ Organising partners: @JBI, @Cochrane, @The Campbell Collaboration, @Institute of Development Studies, The Centre for Evidence-based Health Care (CEBHC) and Applied Health Research Unit (AHRU) at @Oxford Population Health

Cochrane reviews are informing World Health Organization Guidelines for preterm infant care! 👶 🎉 Cochrane Sweden and Cochrane Neonatal have provided the evidence to inform WHO’s updated guidelines on preterm infant care, including treatments like caffeine therapy to improve lung function and outcomes for these vulnerable babies. Preterm birth is a leading cause of infant mortality worldwide, and these evidence-based recommendations will help improve survival and long-term health outcomes. Cochrane Sweden is now working on adapting the WHO guidelines for the Swedish healthcare system using the GRADE ADOLOPMENT framework. 🎤 “It’s an efficient way to make tailored recommendations based on solid foundations, without duplicating efforts,” says Matteo Bruschettini, Director of Cochrane Sweden. 🎤 "We're working to integrate existing guidelines into the Swedish setting, saving time and resources by adopting, adapting, and adding contextual evidence where necessary," says Martin Ringsten, Project Coordinator at Cochrane Sweden. The contextualization of global guidelines for national settings shows how Cochrane reviews can directly shape healthcare policy and practice, making a real impact both locally and internationally. ➡️ Read more about this here: https://lnkd.in/gWhk8wiu Nordic GRADE Network #EvidenceBasedHealthcare #PretermCare #PremieCare #NeonatalCare #Guidelines #WHO #CochraneNeonatal #GRADE #CochraneSweden

There are lots of ways for patients and carers to get involved in our work. 💜 Volunteer and make a global impact to health! ⬇️⬇️⬇️ https://lnkd.in/g9f5ufvV

Treating #PMS and premenstrual dysphoric disorder #PMDD with selective serotonin reuptake inhibitors In August 2024, we published the latest update of the Cochrane Review of the effect of selective serotonin reuptake inhibitors on women with premenstrual syndrome and premenstrual dysphoric disorder. In this podcast, two of the authors, Jeppe Bennekou Schroll and Cecilie Jespersen, both from Cochrane Denmark, talk about the need for the review and its latest findings. 🎧 Listen to the #CochranePodcast - all the evidence in just 7 mins https://lnkd.in/gFQr8ASw 🤓 Read the full #SystematicReview https://lnkd.in/gM84MsvP Jespersen C, Lauritsen MP, Frokjaer VG, Schroll JB. Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder. Cochrane Database of Systematic Reviews 2024, Issue 8. Art. No.: CD001396. DOI: 10.1002/14651858.CD001396.pub4.

We’re #hiring a new Managing Editor working remotely. Apply today or share this post with your network.

Don't miss out! 🌍 Register for this FREE webinar series on building climate-resilient health systems. Everyone welcome! ➡️ More info and registration: https://lnkd.in/g4jYDBT7

🎉 Congratulations to Marwin Weber, winner of the 2024 Thomas C Chalmers Award for Best Poster Presentation at the Global Evidence Summit! 🏆 The Thomas C Chalmers Award for Best Poster Presentation recognises outstanding contributions to advancing systematic review methods. Marwin, a Research Assistant at the Institute for Evidence in Medicine at the Universitätsklinikum Freiburg, won for his poster presentation titled 'Non-dissemination in qualitative health research – a retrospective cohort study of conference abstracts.' 📚 Marwin's research sheds light on dissemination bias—a systematic error resulting from the selective non-dissemination of studies and findings. Given its harmful impact in quantitative research, it is crucial to consider dissemination bias in qualitative research as well. His study quantified the extent of non-dissemination of qualitative studies and identified the factors associated with it, revealing that almost one-quarter of qualitative health studies remained unpublished within at least six years. 🎤 "I feel very fortunate to conduct this research together with excellent, reliable, appreciative and helpful colleagues. This achievement would not have been possible without them. Personally, I feel honoured, especially as I consider myself a novice in this field. This recognition helps me to put prior uncertainties regarding decisions into perspective. I hope to use this validation as a foundation for my future research work. Additionally, I believe this award provides a valuable opportunity to highlight the importance of this topic." 👉 Read more about Marwin's work and access a PDF of his award-winning poster: https://lnkd.in/gkpCs2wy 👏👏👏 Join us in congratulating Marwin in the comments!

Family‐based interventions versus standard care for people with schizophrenia. 🤗 #Family plays a key role in caring for relatives, which in turn probably contributes to high levels of distress and burdens for the family, potentially increasing the risk of relapse in patients. Family interventions focus on improving the families’ knowledge, emotions, behaviours, and the overall family environment, thereby benefiting family well‐being and management of patients' symptoms. Despite concerns about privacy and burdening their families, most people with #schizophrenia consent to have their families involved in their care. 📚 🔍 This #SystematicReview looked at the evidence from 26 RCTs in this review, with 1985 people with schizophrenia or schizophrenia‐like disorders, and 2056 family members. Most family‐based interventions were conducted on a weekly or biweekly basis, with duration ranging from five weeks to two years. Key messages • Family interventions may reduce relapse in individuals with schizophrenia. • Family interventions probably reduce #caregiver burden and may improve expressed emotion (i.e. adverse family environment including family relationships and interaction patterns) in families of individuals with schizophrenia. • Additional studies are needed to allow any strong conclusions about family interventions for people with schizophrenia and their families. 🚩 Future large and well‐designed RCTs are needed to provide more reliable evaluation of effects of family interventions in people with schizophrenia or schizophrenia‐like disorders and their families. 🤓 Read the full #CochraneReview and #PlainLanguage summary https://lnkd.in/gwhihwSj Chien WT, Ma DC, Bressington D, Mou H. Family‐based interventions versus standard care for people with schizophrenia. Cochrane Database of Systematic Reviews 2024, Issue 10. Art. No.: CD013541. DOI: 10.1002/14651858.CD013541.pub2.

Cochrane is proud to highlight that the Global Evidence-Local Adaptation (GELA) project has been featured in the October 2024 issue of the World Health Organization (WHO) Bulletin. The GELA project aims to improve child health by adapting global health guidelines to better suit the local needs of #Malawi, #Nigeria, and #SouthAfrica. In this collaborative effort, Cochrane plays a vital role by providing #EvidenceSynthesis expertise and building local capacity. This ensures that the recommendations developed are contextually relevant and effectively address the health priorities of these communities. 📜 Read 'Building sustainable capacity to adopt, adapt or develop child health guidelines, Malawi, Nigeria and South Africa' here: https://lnkd.in/gCAg3eyr Tamara Kredo, Solange Durao, Emmanuel Effa, Celeste Naude, Michael McCaul, Amanda Brand, Simon Lewin, Claire Glenton, Susan Munabi-Babigumira, Elodie Besnier, Trudy Leong, Bey Schmidt, Nyanyiwe Mbeye, Ameer Hohlfeld, Anke Rohwer, Tandekile Lublwana Hafver, Nicolas Delvaux, Lungiswa Nkonki, Funeka Bango, Emma Thompson, and Sara Cooper

The World Health Organization (WHO) has recently launched new guidance on best practices for clinical trials. The document aims to reinforce global standards in the organization, design, conduct, analysis and reporting of clinical trials. It responds to calls in World Health Assembly resolution 75.8, which emphasized the urgent need to enhance both global and national clinical trial ecosystems to generate high-quality evidence on health interventions. The WHO guidance offers practical recommendations for national health authorities, regulatory bodies, funders, and others to facilitate effective clinical trials. Key recommendations focus on: ✨improving trial design to ensure the relevance of research; ✨ Emphasis on scientific and ethical standards; ✨ Strengthening of capacity and support for sustainable research infrastructure; ✨ Enhancing clinical trial transparency; and ✨ Reforms to enable underrepresented groups to participate in clinical trials. Cochrane’s Editor in Chief, Dr Karla Soares-Weiser, contributed to the technical advisory group established to support the resolution and this guidance. Eva Madrid Aris, the Lead of Cochrane’s new Iberoamérica Evidence Synthesis Unit, spoke on the launch panel, emphasising the importance of collaboration between clinical trialists and the evidence synthesis community. She stated, “Disregarding existing evidence leads to redundant findings and fails to prioritise the gaps that we need to fill, missing the opportunity to resolve clinical uncertainties with clinical trials.” 💜 Learn more: https://lnkd.in/gMSNxyU8 📜 Read 'Guidance for best practices for clinical trials': https://lnkd.in/gjtMXmXt 📽️ Watch the video of the launch event: https://lnkd.in/gfUq63fM #ClinicalTrials #EvidenceBasedMedicine #HealthInterventions #HealthResearch #PublicHealth #TrialDesign #EvidenceSynthesis